Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
null
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
null
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
#Product Stage #Management Changes
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
#Product Stage
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
#Product Stage #FDA approved/pending approval
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
#Product Stage #Partners
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
#Product Stage
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition
#Acquisition
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study
#Product Stage #Acquisition
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
#Product Stage #Partners #FDA approved/pending approval
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan
#Acquisition
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy
#Product Stage #FDA approved/pending approval
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
#Product Stage
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza
#Product Stage #FDA approved/pending approval
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
#Product Stage
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study
#Product Stage
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure
#Product Stage #Layoffs
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
#Product Stage #Investment
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
#Product Stage #Partners
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
#Product Stage
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
#Product Stage #Partners
Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis
#Product Stage #Partners
Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
#Product Stage #FDA approved/pending approval #Partners
Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025
#Product Stage
Biotech Alert: Searches spiking for these stocks today
#Product Stage #FDA approved/pending approval
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases
#Product Stage
Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
#Product Stage
Chemomab Announces New Medical and Clinical Appointments
#Management Changes #Product Stage
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
#Product Stage
New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis
#Product Stage
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
#Product Stage #Partners
Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
#Product Stage #Partners
Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
#Product Stage #Investment #FDA approved/pending approval
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
undefined
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
undefined
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
#Partners
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
undefined
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
undefined
Chemomab Therapeutics to Present at October 2024 Investor Conferences
#Investment
Chemomab Therapeutics to Present at September 2024 Investor Conferences
undefined
Chemomab jumps on positive liver scarring trial results
#Investment
תוצאות הניסוי הקליני שהקפיצו את מניית חברת התרופות הישראלית
#Investment #Public Trading #Customers
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
#Investment
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
#Investment
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
#Investment
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
#Public Trading
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
#Investment #Expand
Chemomab Therapeutics Announces $10 Million Private Placement
#Investment
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
#Investment #Expand
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
#Investment #Expand
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
null
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
#Investment
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
#Public Trading
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
#Management Changes
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
#Investment
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
#Investment
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
#Customers, Partners
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
#Expand
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
#Management Changes #Investment
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference
#Management Changes
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
#Investment
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
undefined
Chemomab Therapeutics to Participate in Upcoming Investor Conferences
#Management Changes
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
#Investment, Expand
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024
#Investment
Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis
#Investment, Expand
Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis
#Investment #Expand
Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023
#Investment, Expand
Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
#Investment
Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement
#Public Trading
Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update
#Investment
Chemomab Therapeutics to Present at Upcoming Scientific Conferences
#Expand
Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference
#Investment #Expand
Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
#Investment #Management Changes
Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update
undefined
Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis
#Customers
Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023
#Customers #Partners
Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023
#Customers
Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update
#Management Changes
Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis
#Customers
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
#Partners
Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update
undefined
Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference
undefined
Chemomab Therapeutics to Present at Upcoming Scientific Conferences
#Partners #Expand
Chemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate Update
undefined
Chemomab Therapeutics to Provide a Corporate Update on April 17, 2023
undefined
Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update
undefined
Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference
#Management Changes
Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis
undefined
Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients
undefined
Chemomab Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis
#Investment
Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy
undefined
Chemomab Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
undefined
Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19
undefined
Chemomab Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Business Update
undefined
Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities
#Management Changes #Expand
Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
#Investment #Management Changes
Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
undefined
Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update
undefined
Chemomab Awarded New U.S. Patent for CM-101, Its First-in-Class CCL24 Neutralizing Antibody
#Customers #Partners
Data Supporting Role of Chemomab's Novel Therapeutic Target CCL24 in Systemic Sclerosis Presented at EULAR 2022
#Expand
Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer
#Management Changes #Expand
Chemomab Completes Merger with Anchiano Therapeutics
#Acquisition #Public Trading #Investment #Management Changes
Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing
#Acquisition #Investment
Chemomab Announces First Patient Enrolled in Phase IIa Study of CM-101 for the Treatment of Patients with Primary Sclerosing Cholangitis
#Customers
Chemomab Announces Positive Phase Ib Results of its SPARK study testing CM-101 in NAFLD patients
#Acquired-by
Anchiano Therapeutics jumps after Chemomab merger
#Acquisition #Expand
Chemomab Announces Late-Breaking Presentation of CM-101 First Evidence of Anti-Fibrotic Activity in NAFLD Patients at the AASLD's The Liver Meeting Digital Experience™ 2020
#Customers #Partners
Chemomab Receives European Orphan Drug Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis
#Customers
Chemomab Receives Regulatory Approval to Commence a Phase II Clinical Trial for CM-101 as Treatment of Primary Sclerosing Cholangitis
#Investment
ChemomAb Ltd. Announces Issuance of Composition of Matter Patent for CM-101 and Reinforces its IP Portfolio
#Investment
ChemomAb Ltd., Announces Data from Phase 1 Study of CM-101 Subcutaneous Formulation Demonstrating Comparable Exposure to The Intravenous CM-101 Formulation
#Investment
ChemomAb Doses First Patient in Phase 1b Clinical trial of CM-101 in Patients With Non-Alcoholic Fatty Liver Disease
undefined
Led by OrbiMed Israel and Peter Thiel, ChemomAb Raises $10 Million in Series B Funding
#Investment